Journal
FUTURE ONCOLOGY
Volume 10, Issue 15, Pages 2423-2427Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/fon.14.159
Keywords
gastrointestinal stromal tumor; imatinib; metastatic gastrointestinal stromal tumor; pleural effusion; toxicity
Categories
Ask authors/readers for more resources
Gastrointestinal stromal tumors are rare malignancies characterized by c-kit and PDGFR- mutations targeted by imatinib. Pleural effusion is a very rare side effect of imatinib treatment. A 65-year-old female with metastatic gastrointestinal stromal tumor developed electrolyte imbalance, severe peripheral edema and progressively worsening dyspnea 2 months after starting imatinib. Having excluded cardiovascular and pulmonary disorders, imatinib was discontinued and prednisone 25 mg orally daily was begun. The patient's condition improved substantially over the next 48 h with a progressive decrease in dyspnea and a reduction in pleural effusion and peripheral edema. All side effects had resolved within 1 month. In view of the partial response obtained, the patient re-started imatinib after a 1-week interruption. Prednisone was maintained and there was no further toxicity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available